Literature DB >> 18215118

The Rb/E2F pathway and Ras activation regulate RecQ helicase gene expression.

Yongqing Liu1, Shahenda El-Naggar, Brian Clem, Jason Chesney, Douglas C Dean.   

Abstract

Disruption of the Rb (retinoblastoma protein)/E2F cell-cycle pathway and Ras activation are two of the most frequent events in cancer, and both of these mutations place oncogenic stress on cells to increase DNA replication. In the present study, we demonstrate that these mutations have an additive effect on induction of members of the RecQ DNA helicase family. RecQ activity is important for genomic stability, initiation of DNA replication and telomere maintenance, and mutation of the BLM (Bloom's syndrome gene), WRN (Werner's syndrome gene) or RECQL4 (Rothmund-Thomson syndrome gene) family members leads to premature aging syndromes characterized by genetic instability and telomere loss. RecQ family members are frequently overexpressed in cancers, and overexpression of BLM has been shown to cause telomere elongation. Concomitant with induction of RecQ genes in response to Rb family mutation and Ras activation, we show an increase in the number of telomeric repeats. We suggest that this induction of RecQ genes in response to common oncogenic mutations may explain the up-regulation of the genes seen in cancers, and it may provide a means for transformed cells to respond to an increased demand for DNA replication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18215118     DOI: 10.1042/BJ20070975

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  9 in total

1.  Human RecQL4 helicase plays critical roles in prostate carcinogenesis.

Authors:  Yanrong Su; Jarah A Meador; Gloria M Calaf; Luca Proietti De-Santis; Yongliang Zhao; Vilhelm A Bohr; Adayabalam S Balajee
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

2.  Endosulfan induces apoptosis by activating the negative regulation pathway of cell cycle and death receptor pathway in spermatogenic cells.

Authors:  Fang-Zi Guo; Ying Xu; Li-Hua Ren; Jin Zhang; Feng Zhang; Junchao Duan; Xian-Qing Zhou; Zhi-Wei Sun
Journal:  Toxicol Res (Camb)       Date:  2017-01-06       Impact factor: 3.524

3.  Altered RECQ Helicase Expression in Sporadic Primary Colorectal Cancers.

Authors:  Victoria Valinluck Lao; Piri Welcsh; Yanxin Luo; Kelly T Carter; Slavomir Dzieciatkowski; Suzanne Dintzis; Jane Meza; Nora E Sarvetnick; Raymond J Monnat; Lawrence A Loeb; William M Grady
Journal:  Transl Oncol       Date:  2013-08-01       Impact factor: 4.243

4.  Werner syndrome as a hereditary risk factor for exocrine pancreatic cancer: potential role of WRN in pancreatic tumorigenesis and patient-tailored therapy.

Authors:  Stephen G Chun; Nelson S Yee
Journal:  Cancer Biol Ther       Date:  2010-09-22       Impact factor: 4.742

Review 5.  The impact of cellular senescence in cancer therapy: is it true or not?

Authors:  Yi Zhang; Jin-ming Yang
Journal:  Acta Pharmacol Sin       Date:  2011-09-12       Impact factor: 6.150

6.  WRN helicase promotes repair of DNA double-strand breaks caused by aberrant mismatch repair of chromium-DNA adducts.

Authors:  Alma Zecevic; Haley Menard; Volkan Gurel; Elizabeth Hagan; Rosamaria DeCaro; Anatoly Zhitkovich
Journal:  Cell Cycle       Date:  2009-09-02       Impact factor: 4.534

7.  Recurrent RECQL4 imbalance and increased gene expression levels are associated with structural chromosomal instability in sporadic osteosarcoma.

Authors:  Georges Maire; Maisa Yoshimoto; Susan Chilton-MacNeill; Paul S Thorner; Maria Zielenska; Jeremy A Squire
Journal:  Neoplasia       Date:  2009-03       Impact factor: 5.715

8.  Genetically engineered mouse models and human osteosarcoma.

Authors:  Alvin Jm Ng; Anthony J Mutsaers; Emma K Baker; Carl R Walkley
Journal:  Clin Sarcoma Res       Date:  2012-10-04

Review 9.  Protein sequestration at the nuclear periphery as a potential regulatory mechanism in premature aging.

Authors:  Leonid Serebryannyy; Tom Misteli
Journal:  J Cell Biol       Date:  2017-10-19       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.